ASSOCIATION OF DOOR TO DIURETIC TIME ON MORTALITY AND MORBIDITY IN ACUTE HEART FAILURE
Main Article Content
Keywords
acute heart failure, reduced ejection fraction, preserved ejection fraction, readmission, mortality
Abstract
This study was prospective, observational study of patients hospitalized for acute heart failure (AHF). All patients were followed up for six months after the index hospitalization. Early group (n = 137) received IV diuretics within 90 minutes while as Delayed group (n = 293) received IV diuretics after 90 minutes. Demographic parameters like age, gender and comorbid illness was compared in patients in Early Group and Delayed Group and the association was found to be statistically insignificant (p >0.05). Insignificant statistical difference was observed when smoking status was compared between two study groups. There were 21.9% smokers in Early Group compared to 17.4% smokers in Delayed Group. On echocardiography, heart failure with preserved ejection fraction (HFpEF) was observed in 48.1% patients, heart failure with reduced ejection fraction (HFrEF) was seen in 39.1% patients and 12.8% patients had heart failure with midrange ejection fraction (HFmrEF). In-hospital mortality was higher in Delayed Group (12.3%) compared to Early Group (5.1%) with significant statistical difference (p < 0.05). Mean length of hospitalization was shorter in Early Group (14.7 days) compared to 17.3 days in Delayed Group (P < 0.05). Readmission at 1 month in two study groups was found to be statistically insignificant (p>0.05) with 13.9% in Early Group compared to 16.4% in Delayed Group. Readmission at 6 month was again higher in Delayed Group 12.3% versus 9.5% in Early Group with an insignificant statistical association (p > 0.05). At one month significantly higher mortality was observed in Delayed Group (14.3%) compared to 7.3% in Early Group (p<0.05). At 6 month, there was higher mortality in Delayed Group (22.9%) compared to 13.1% in Early Group with a statistically significant association between (p <0.05).
References
2. McMurray JJ and Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart (British Cardiac Society), 2000;83(5):596–602.
3. Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney International, 1984;26(2):183–189.
4. Cook JA, Smith DE, Cornish LA, Tankanow RM, Nicklas JM, Hyneck ML. Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure. Clin Pharm Therap, 1988;44(5):487–500.
5. Brater DC, Seiwell R, Anderson S, Burdette A, Dehmer GJ, Chennavasin P. Absorption and disposition of furosemide in congestive heart failure. Kidney International, 1982; 22(2): 171–176.
6. Odlind BO, Beermann B. Diuretic resistance: reduced bioavailability and effect of oral frusemide. BMJ, 1980;280(6231):1577. https://doi.org/10.1136/bmj.280.6231.1577.
7. Brater DC. Pharmacokinetics of loop diuretics in congestive heart failure. British Heart Journal, 1994;72(2 Suppl):S40–S43.
8. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology, 2001;96(3-4):132–143.
9. Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB et al. Diuretic resistance predicts mortality in patients with advanced heart failure. American Heart Journal, 2002;144(1):31–38.
10. Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O'Connor CM et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014 May 14;35(19):1284-93.
11. Voors AA, Davison BA, Teerlink JR, Felker GM, Cotter G, Filippatos G et al. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. Eur J Heart Fail. 2014 Nov; 16(11): 1230-40.
12. Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, Tang WH. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014 Mar 1; 7(2): 261-70.
13. Somberg JC, Molnar J. The management of acute heart failure and diuretic therapy. American Journal of Therapeutics, 2009;16(1):93–97.
14. Cowie MR, Anker SD, Cleland JGF, Felker GM, Filippatos G, Jaarsma T et al. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail. 2014 Dec;1(2):110-145.
15. Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S et al. Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. J Am Coll Cardiol. 2017 Jun 27;69(25):3042-3051.
16. Park JJ, Kim SH, Oh IY, Choi DJ, Park HA, Cho HJ et al. The Effect of Door-to-Diuretic Time on Clinical Outcomes in Patients With Acute Heart Failure. JACC Heart Fail. 2018 Apr;6(4):286-294.
17. Iqbal AM, Mohammed SK, Zubair N, Mubarik A, Ahmed A, Jamal SF et al. The impact of door to diuretic time in acute heart failure on hospital length of stay and in-patient mortality. Cureus. 2021 Jan 16;13(1):e12742. doi: 10.7759/cureus.12742.
18. Viriyanukulvong KV, Han-Gla AH, Phannajit JP, Ariyachaipanich AA. Door-to-Furosemide time effects on in-hospital mortality and length of stay in acute heart failure patients. European Heart Journal. 2021 Oct 1;42(Supplement_1):ehab724-0897.
19. Mir J, Mumtaz S, Alan M, Bell T, Malik A. Effect of door to diuretic time in acute heart failure. Journal of Cardiac Failure. 2020;26(10):S47. DOI:10.1016/j.cardfail.2020.09.138.
